Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Healthcare Collaboration and Partnerships

Sponsored by

Finalist

Abbott's Small Steps to Change programme in collaboration with NHS rheumatologists to implement Treat to Target

Abbott Laboratories in association with DNA Medical Communications


Summary of work

The Treat to Target principles in rheumatoid arthritis include early referral, regular assessment and early diagnosis to make disease remission a realistic target for patients.

Evidence shows that earlier treatment improves patient outcomes. However, access to biologics, if appropriate, is often delayed as they are second‐line treatment and patients are often not reviewed regularly enough or treated to a target, which can make treatment decisions subjective. 

Abbott UK rolled‐out Treat to Target nationally to improve the management of patients, and improve the access to biologics for patients who require this treatment. Partnership with the most influential UK KOLs (including the 2011 European Rheumatology Professional Body (EULAR) chair) led to the inclusion of Treat to Target in the latest SIGN guidance and publication of a consensus on standardising assessment using DAS28 in a peer‐reviewed journal. 

Treat to Target was delivered through a revolutionary programme, Small Steps to Change (SSTC), allowing rheumatologists to break change into small steps, through low-/no-cost solutions delivering target‐driven regimens. SSTC changed routine practice in over 40 units with huge improvements in referral rates (10.76 to two weeks), assessment completion rates (16.7 per cent to 78.9‐100 per cent) and fewer patients with high disease activity at referral (40 per cent vs 25 per cent).

 

 

Executive summary as submitted


PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

digital launch
How can virtual pharma companies de-risk new product launches?
The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market...
Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...

Infographics